Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):657-658. doi: 10.1038/s41391-021-00483-5. Epub 2022 Jan 4.

Authors

Raj Tiwari¹, Katherine Lajkosz², Neil Fleshner², Christopher J D Wallis²

Affiliations

¹ Division of Urology, University of Toronto, Toronto, ON, Canada. raj.tiwari@uhn.ca.
² Division of Urology, University of Toronto, Toronto, ON, Canada.

PMID: 34980879
DOI: 10.1038/s41391-021-00483-5

No abstract available

Publication types

Review

MeSH terms

Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / etiology
Gonadotropin-Releasing Hormone
Heart Disease Risk Factors
Humans
Male
Prostatic Neoplasms*
Risk Factors

Substances

Gonadotropin-Releasing Hormone